Amgen logged a -0.4% change during today's morning session, and is now trading at a price of $249.0 per share.
Amgen shares moved -0.8% over the last 52 weeks, with a high of $296.67 and a low of $223.3. During this time, the stock outperformed the S&P 500 index by 5.0%. As of January 2022, the company's 50-day average price is $239.0. Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The large-cap Health Care company has 25,200 full time employees and is based in Thousand Oaks, CA. Amgen has returned a 3.1% dividend yield over the last 12 months.
a Flat EPS Growth Trend with a Highly Leveraged Balance Sheet:
|Gross Margins Growth||n/a||-6.88%||-0.79%||0.66%|
|Operating Margins Growth||n/a||-13.04%||-2.22%||3.12%|
|Net Margins Growth||n/a||-14.89%||-20.62%||9.74%|
|Earnings Per Share||$12.88||$12.31||$10.28||$12.1|
|Diluted Shares (MM)||609||590||573||534|
|Free Cash Flow (MM)||$9,150||$10,497||$9,261||$8,785|
|Capital Expenditures (MM)||-$618||-$608||-$880||-$936|
|Net Debt / EBITDA||2.87||3.51||3.54||4.45|
Amgen Is Overvalued:
Compared to the Health Care sector's average of 24.45, Amgen has a trailing twelve month P/E ratio of 20.6 and, according to its EPS guidance of 18.7, an expected P/E ratio of 13.3. Amgen's PEG ratio is 2.02 based on its 9.8% compound average growth rate of historical and projected earnings per share. This suggests that the company's shares are overvalued.
Amgen's P/B ratio is 36.3 compared to its sector average of 4.16. The company is likely overvalued in terms of its net asset value. The company's shares are currently trading 481.4% above their fair value as expressed by Benjamin Graham's formula:
√(22.5 * 4-year average EPS * book value per share) = √(22.5 * 11.89 * 6.856) = $42.83
Amgen Is the Subject of Mixed Market Indicators:
21 analysts are following Amgen and have set target prices ranging from $175.0 to $325.0 per share. On average, they have given the company a rating of hold. At the current price of $249.0, AMGN is trading -3.36% away from its average analyst target price of $257.67 per share, implying an analyst consensus of some upside potential for the stock.
The company has a very low short interest since 1.5% of the company's shares are tied to short positions. Institutions own 79.8% of Amgen's shares, while the insider ownership rate stands at 0.22%. The biggest shareholder is Blackrock Inc. with a 9% stake in the company worth approximately $12,080,145,360.